Autonomous agent-based AI that discovers novel therapeutic strategies within the Bird of Prey framework. Not just prediction, but intelligent vector design that reasons through complex biological constraints.
Traditional approaches to gene therapy design leave enormous therapeutic potential unexplored.
Most AI tools optimize one component at a time. Such as capsid performance, promoter strength, or payload size. This ignores the complex interactions between positional effects, cell-specific functionality, and combinatorial gene relationships that determine real-world therapeutic efficacy.
Predictive models tell you what might work, but not why or how to iterate. They lack the reasoning capabilities to guide you through the design space, forcing you to run expensive validation cycles on suboptimal candidates.
Most AI approaches design vectors without considering manufacturability, stability, or platform constraints. Beautiful in silico designs fail to consider commercial production protocols & requirements, balancing therapeutic effect and commercial feasibility, wasting months of development time and potentially millions in internal or outsourced manufacturing & protocol costs.
Existing AI systems optimize known therapeutic strategies but cannot discover novel gene combinations that produce emergent effects. The most transformative therapies, those leveraging synergistic multi-target approaches, remain hidden in unexplored design space.
Agent-based reasoning that understands the full complexity of therapeutic vector design
Unlike predictive models that just score options, Noctua uses autonomous agents that reason through design decisions. It iteratively explores the design space, understanding trade-offs and constraints to guide you toward optimal solutions. Think of it as an expert collaborator, not a prediction engine.
Noctua is trained specifically on the Bird of Prey modular platform, understanding real manufacturing constraints, stability requirements, and production realities. Every recommendation is grounded in what can actually be built, eliminating the gap between computational design and physical production.
Noctua simultaneously optimizes across three critical dimensions: positional effects within the vector, cell-type-specific functionality, and combinatorial gene interactions. This holistic approach captures the complex interdependencies that single-variable optimization misses entirely.
Noctua discovers novel gene combinations that produce emergent therapeutic effects. By analyzing unbiased biological data stripped of historical assumptions, it identifies synergistic multi-target approaches that traditional methods would never find. This is where breakthrough therapies emerge.
Noctua learns from multiple data sources to deliver insights tailored to your therapeutic programs
Bias-stripped public datasets analyzed for pure biological function, providing a foundation of validated biological knowledge
Custom data generated from Bird of Prey platform validation, capturing real-world performance across diverse conditions
Integration of your own experimental data creates a custom model that understands your specific disease targets and development constraints
A collaborative approach that combines AI intelligence with your therapeutic expertise
We analyze your disease targets, therapeutic goals, and existing data. Noctua begins learning your specific context while we map the design space for your therapeutic programs.
Noctua generates optimal vector designs within the BoP framework, reasoning through module selection, positioning, and combinations. You receive explained recommendations with clear rationale for each design decision.
As you generate experimental data, Noctua continuously refines its recommendations. The AI learns from your results, becoming increasingly tailored to your specific therapeutic challenges and opportunities.
Let Noctua AI guide your vector design within the Bird of Prey framework